3-morpholinopropylamine : A member of the class of morpholines that is morpholine substituted by a 3-aminopropyl group a the N atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 61055 |
| CHEMBL ID | 158697 |
| CHEBI ID | 86554 |
| SCHEMBL ID | 19922 |
| Synonym |
|---|
| BB 0216500 |
| 3-morpholin-4-yl-propylamine |
| smr000147739 |
| MLS000556422 |
| inchi=1/c7h16n2o/c8-2-1-3-9-4-6-10-7-5-9/h1-8h |
| ai3-52553 |
| n-(3-aminopropyl)morfolin [czech] |
| nsc 1081 |
| einecs 204-590-2 |
| brn 0105104 |
| 3-morpholinopropanamine |
| gamma-morpholinopropylamine |
| OPREA1_150673 |
| 4-aminopropylmorpholine |
| wln: t6n dotj a3z |
| 4-(3-aminopropyl)morpholine |
| 4-(.gamma.-aminopropyl)morpholine |
| morpholine, 4-aminopropyl- |
| 1-amino-3-morpholinopropane |
| 4-morpholinepropylamine |
| n-aminopropylmorpholine |
| n-(3-aminopropyl)morpholine |
| nsc1081 |
| 3-morpholinopropylamine |
| 123-00-2 |
| morpholine, n-aminopropyl- |
| 4-morpholinepropanamine |
| nsc-1081 |
| (3-aminopropyl)morpholine |
| .gamma.-morpholinopropylamine |
| morpholine, 4-(3-aminopropyl)- |
| 3-morpholinopropylamine, liquid |
| FC1F27D2-1429-41AC-9F03-C277D41006FA |
| morpholine, n-(3-aminopropyl)- |
| A0409 |
| 3-morpholin-4-ylpropan-1-amine |
| 3-morpholinopropan-1-amine |
| chebi:86554 , |
| CHEMBL158697 , |
| 3-(morpholin-4-yl)propan-1-amine |
| STK802951 |
| AKOS000119857 |
| A1799 |
| NCGC00246332-01 |
| 3-(4-morpholinyl)-1-propanamine |
| dtxsid4041521 , |
| dtxcid2021521 |
| NCGC00255491-01 |
| cas-123-00-2 |
| tox21_302076 |
| BMSE000981 |
| BMSE000971 |
| HMS2384K03 |
| n-(3-aminopropyl)morfolin |
| unii-9a09425qd6 |
| 4-27-00-00411 (beilstein handbook reference) |
| 9a09425qd6 , |
| 3-morpholin-4-ylpropylamine |
| FT-0616577 |
| 1-morpholino-3-aminopropane |
| 3-(n-morpholino)-1-aminopropane |
| 3-(4-morpholinyl)-propan-1-amine |
| 4-(3-aminopropyl)-morpholine |
| (3-morpholin-4-ylpropyl)amine |
| 4-(3aminopropyl)morpholine |
| n-(3-aminopropyl)morpholin |
| 3-(4-morpholinyl)-1-aminopropane |
| 3-(4-morpholinyl)propylamine |
| 3-morpholino-propan-1-amine |
| 3-morpholin-4-yl propylamine |
| 3-(4-morpholinyl)-1-propylamine |
| n-(3-aminopropyl)-morpholine |
| 3-morpholino-propylamine |
| 4-(3-aninopropyl)-morpholine |
| 3-(4-morpholinyl)propan-1-amine |
| 3-morpholine-4-yl-propylamine |
| n-(aminopropyl)morpholine |
| [3-(4-morpholinyl)propyl]amine |
| aminopropylmorpholine |
| 3-morpholinylpropylamine |
| 3-(morpholin-4-yl)propylamine |
| 3-aminopropyl morpholine |
| 3-(n-morpholinyl)-1-propylamine |
| 4-(3-aminopropyl) morpholine |
| n-(gamma-aminopropyl)morpholine |
| (3-morpholinopropyl)amine |
| 3-aminopropylmorpholine |
| 3-(4-morpholinyl)-propanamine |
| 3-(morpholin-4-yl)-propylamine |
| n-(3-aminopropyl) morpholine |
| 3-morpholin-4-yl-propan-1-amine |
| SCHEMBL19922 |
| 4-(aminopropyl)morpholine |
| 3-(4-morpholinyl)-1-propanamine # |
| 4-[3-aminopropyl]morpholine |
| 3-morpholino-1-propylamine |
| Q-201446 |
| FD10554 |
| mfcd00006184 |
| F2187-2240 |
| 3-morpholinopropylamine, 98% |
| Z104474506 |
| CS-0008472 |
| Q27159240 |
| STR02269 |
| A850959 |
| EN300-19625 |
| napm |
| bdbm50607380 |
| Class | Description |
|---|---|
| morpholines | Any compound containing morpholine as part of its structure. |
| primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 35.4813 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.0224 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 31.6228 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 1.9953 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Kelch-like ECH-associated protein 1 | Homo sapiens (human) | Kd | 300.0000 | 1.0000 | 1.7667 | 2.4000 | AID1918095 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1918095 | Binding affinity to Keap1 kelch domain (unknown origin) by surface plasmon resonance assay | 2022 | Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21 | Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||